Menu Menu

PEAR 1: Pharmacogenomic Evaluation of Antihypertensive Responses 1

PEAR logo

PEAR was a multicenter prospective interventional trial that included 768 participants aged 17 to 65 years with uncomplicated hypertension. Both candidate gene and GWAS approaches will be used in order to identify genetic determinants of antihypertensive and adverse metabolic responses to thiazide diuretic, beta blocker, or their combination in self-identified Caucasians and African Americans. Participants were randomized to either HCTZ 25 mg or atenolol 100 mg , with 1 dose titration step followed by assessment at least 6 weeks later. Those with a BP >120/>70 continue to move through titration protocol. Home, office, and 24-hour ambulatory blood pressures as well as biologic samples (lipid, glucose, and uric acid) were collected. To date, 39 SNPs have been associated with blood pressure (BP) or hypertension in genome-wide association studies in whites.

PEAR 1 Publications